Characteristics of the 27 study group patients
| Characteristic . | No. . |
|---|---|
| Age at least 60 y [median] | 3 [47] |
| Splenomegaly | 2 |
| Disease phase | |
| Chronic | 17 |
| Second chronic | 1 |
| Accelerated | 9 |
| Duration of disease (mo) | |
| Fewer than 12 | 2 |
| 12-36 | 7 |
| More than 36 | 18 |
| Hemoglobin (< 10 g/dL) | 1 |
| WBC (> 20 × 109/L) | 8 |
| Platelets (> 450 × 109/L) | 6 |
| Reason for change from IFN-α | |
| Hematologic resistance/partial hematologic response | 4/5 |
| Unsatisfactory cytogenetic response | 12 |
| Toxicities with IFN-α | 6 |
| Philadelphia chromosome percent status before PEG IFN-α-2b | |
| 100% | 20 |
| 35%-90% | 4 |
| 15%-30% | 3 |
| Disease status at start of therapy | |
| Active | 19 |
| CHR | 8 |
| Characteristic . | No. . |
|---|---|
| Age at least 60 y [median] | 3 [47] |
| Splenomegaly | 2 |
| Disease phase | |
| Chronic | 17 |
| Second chronic | 1 |
| Accelerated | 9 |
| Duration of disease (mo) | |
| Fewer than 12 | 2 |
| 12-36 | 7 |
| More than 36 | 18 |
| Hemoglobin (< 10 g/dL) | 1 |
| WBC (> 20 × 109/L) | 8 |
| Platelets (> 450 × 109/L) | 6 |
| Reason for change from IFN-α | |
| Hematologic resistance/partial hematologic response | 4/5 |
| Unsatisfactory cytogenetic response | 12 |
| Toxicities with IFN-α | 6 |
| Philadelphia chromosome percent status before PEG IFN-α-2b | |
| 100% | 20 |
| 35%-90% | 4 |
| 15%-30% | 3 |
| Disease status at start of therapy | |
| Active | 19 |
| CHR | 8 |